LYEL - Balance Sheet - Lyell Immunopharma, Inc.

Current Liabilities	53.8 M
Accounts Payable	5.37 M
Short-Term Debt	7.97 M
Other Current Liabilities	40.4 M
Non-Current Liabilities	54.2 M
Long-Term Debt	51 M
Other Non-Current Liabilities	3.25 M

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019
ASSETS
Cash & Cash Equivalents	105.6	145.6	123.6	293.8	140.4	96.7
Short Term Investments	264.9	400.6	516.6	321.0	472.2	339.4
Receivables	0	0	0	0	0	0
Inventory	0	0	0	0	0	0
Other Current Assets	9.1	16.9	11.1	23.0	4.9	8.4
Total Current Assets	379.6	554.7	651.3	626.3	617.5	440.3
PP&E	72.9	142.3	166.3	166.6	124.1	43.7
Intangible Assets	0	0	0	0	0	0
Goodwill	0	0	0	0	0	0
Long Term Investments	32.0	48.5	115.0	330.5	163.4	69.0
Other Long Term Assets	6.3	4.5	5.0	3.9	3.2	2.7
Other Assets	0	0	0	0	0	0
Total Assets	490.9	750.0	937.6	1 127.4	908.3	555.6
LIABILITIES
Accounts Payable	5.4	4.8	3.9	3.2	9.4	2.8
Short Term Debt	8.0	6.3	4.5	1.2	3.6	0.3
Other Current Liabilities	40.4	23.4	28.6	37.4	30.2	14.3
Total Current Liabilities	53.8	34.5	37.0	46.7	49.3	22.0
Long Term Debt	51.0	56.9	126.3	133.3	51.0	27.1
Deferred Tax Income	0	0	0	0	0	(98.4)
Other Liabilities	3.3	3.7	(59.1)	(62.1)	0.5	0
Total Liabilities	108.0	95.1	104.3	197.6	189.8	147.6
EQUITY
Common Stock	29 K	25 K	25 K	24 K	2 K	1 K
Retained Earnings	(1 345.1)	(1 002.1)	(767.5)	(584.4)	(334.1)	(129.7)
Other Accumulative Comprehensive Income/Loss	0.3	94 K	(7.6)	(1.6)	0.3	0.5
Total Equity	382.8	655.0	833.3	929.8	718.4	408.1
Total Liabilities and Equity	490.9	750.0	937.6	1 127.4	908.3	555.6
SHARES OUTSTANDING
Common Shares Outstanding	261.5	251.0	247.1	242.7	246.6	246.6

Free